Ann: Clinuvel commences US Phase III trial of SCE, page-5

re: Ann: Clinuvel commences US Phase III tria... moveonup,

- cash situation continues to create an overhang on the share price...many are still on the sidelines until that's ironed out.

- Will this be another year of promises on updates on cuv9900 that aren't delievered on? Wouldn't surprise me. In August, it will be the 2-year anniversary that we were first told about this new compound, but after all this time, they still haven't started trials on it or given us a clearer indication of what is going on with it

- EPP will get approved, but keep in mind when Wolgen took over 6.5 years ago, the share price was in the low .30s (over $3 in today's 10:1 share price consolidation "stuff") and yet analyst Stanton's price projection would only have the share price slightly above the share price (adjusted for the 10:1 consolidation) when Wolgen took over many moons ago. That's pathetic.

I'm looking forward to 2013 when we get a definite FDA decision date for EPP. Frustrating that we probably won't get a hard decision date from the European regulators.